Hereditary spastic paraplegias, or HSPs, are a genetically diverse group of neurological disorders in which degeneration of the central nervous system’s corticospinal tracts produces progressive stiffness and weakness of the lower limbs. Clinicians distinguish pure forms, in which pyramidal signs dominate the picture, from complicated forms accompanied by additional neurological or systemic features such as cognitive impairment, thinning of the corpus callosum, epilepsy, peripheral neuropathy, or skeletal anomalies. More than 87 distinct genetic loci have been linked to the disease, and 73 causative genes have been cloned to date. Despite this heterogeneity, mutations in SPG4/SPAST, which encodes the spastin protein, remain the single most frequent cause of the autosomal dominant forms, accounting for a substantial share of all diagnosed families worldwide.

Spastin belongs to the AAA family of ATPases, enzymes that harness the energy of ATP hydrolysis to remodel cellular structures. Its best-characterized roles involve membrane trafficking and the regulation of microtubule reorganization, processes critical to the long axons of motor neurons. More than 300 different pathogenic variants in the gene have been described, and symptoms typically emerge between the second and fourth decades of life, though onset can range from early childhood to beyond age 70. Recognizing the gene’s dominance and the variability of its presentation, an international team set out to map the SPG4/SPAST mutation profile across three continents and to correlate specific variants with the clinical features they produce.

Between 2001 and 2025, the researchers recruited 726 patients diagnosed with HSP, including 628 familial and 98 sporadic cases, drawn from Italy, Brazil, and Japan. The cohort comprised 313 probands from families with pure or complicated disease, and clinical assessments were performed by movement disorder specialists using standardized instruments including the Spastic Paraplegia Rating Scale. Genetic analysis combined Sanger sequencing of all 17 coding exons of SPG4/SPAST with whole-exome or whole-genome sequencing in selected patients and multiplex ligation-dependent probe amplification to detect large genomic rearrangements that shorter-read methods can miss. Healthy control groups from all three countries provided comparison data.

The genetic results were revealing. Overall, 60.9 percent of patients carried no pathogenic SPAST variant, underscoring the extensive genetic heterogeneity of HSP. Among the rest, sequencing identified 52 different heterozygous mutations in 263 autosomal dominant and 21 sporadic cases. Missense mutations were the largest class at 39.2 percent, followed by splice-site mutations, small deletions, nonsense mutations, insertions, and large rearrangements detected by MLPA, which accounted for 15.7 percent. Four novel variants were identified, absent from population databases and from nearly 400 controls, and all co-segregated with disease in their families. Notably, patients carrying missense mutations experienced an earlier median onset, at 36 years, compared with 42 years for carriers of other mutational classes.

Two of the novel variants carried particular weight. A missense change designated c.1382T>G, producing a p.Leu461Arg substitution within the protein’s AAA domain, was found in 18 unrelated patients from seven Italian families who all shared a common haplotype, pointing to a founder effect. Meanwhile, a small deletion of exon 13 appeared in ten unrelated patients from one Brazilian and two Japanese pedigrees, though haplotype analysis suggested these represented independent mutational events. Multivariate regression confirmed that SPG4 mutation status was independently predicted by later age at onset, a predominantly pure phenotype, lower disability stage, and a familial inheritance pattern, consistent with the gene’s established profile.

The most dramatic discovery emerged from the complicated cases. Among 72 SPG4 patients with complicated disease, foot deformities and cognitive deficits were the leading complications. Remarkably, all 18 affected individuals from the seven Italian families carrying the novel p.Leu461Arg variant had developed features compatible with early-onset dementia, and the same association held in the Brazilian and Japanese families carrying the exon 13 deletion. In every family member diagnosed with early-onset dementia, cerebrospinal fluid analysis showed a decreased Aβ42/Aβ40 ratio, consistent with cerebral amyloid plaque accumulation, while p-tau181 levels remained normal or low, indicating an absence of significant tau pathology or neurofibrillary tangle formation.

Autopsy studies on four patients cemented the pathological picture. Brain examination of a 64-year-old Italian patient carrying the novel variant revealed severe atrophy of the frontal, temporal, and parietal lobes, the hippocampus, amygdala, and entorhinal cortex, alongside a spinal cord thinner than normal with degeneration of the corticospinal tracts. Microscopically, the cortex was laden with senile plaques with congophilic cores and neuritic pathology, yet cotton wool plaques, neurofibrillary tangles, and Lewy bodies were entirely absent, and no abnormal α-synuclein or TDP-43 aggregates were detected. The case was classified as plaque-only dementia, scoring A3-B0-C3 on the National Institute on Aging–Alzheimer’s Association ABC system, with frequent neuritic plaque density by CERAD criteria. Comparable findings were confirmed in the other autopsied patients from Brazil and Japan.

Neuroimaging reinforced the clinical observations. Brain MRI in SPG4 patients with cognitive issues showed cerebral atrophy, particularly of the temporal lobes, while patients with intellectual disability displayed a thin corpus callosum without cerebellar involvement or white matter abnormalities. Amyloid PET imaging with 18F-flutemetamol in patients with early-onset dementia revealed cortical tracer binding consistent with substantial β-amyloid deposition, with Centiloid scores exceeding 50, even in individuals lacking overt neuropathological confirmation. Intriguingly, all autopsy-confirmed cases were homozygous for the APOE ε4 allele, a genotype known to foster a biological environment permissive to amyloid-rich, plaque-dominated dementia, and among all cognitively impaired patients, two-thirds were ε4 homozygotes.

The authors propose that these SPG4 variants may define a new disease manifestation: a form of hereditary spastic paraplegia complicated by an atypical, plaque-only pathological subtype of dementia. Because whole-exome and whole-genome sequencing excluded mutations in other dementia-related genes, including those classically associated with Alzheimer’s disease, the mutated spastin protein itself appears to be the likely culprit, though the precise mechanism linking microtubule dysfunction to amyloid accumulation remains unknown. The study also found that 21 percent of ostensibly sporadic cases carried SPG4 mutations, a rate higher than in small families with two affected members, suggesting that the boundary between familial and sporadic HSP is blurrier than previously assumed, with de novo mutations, incomplete penetrance, and misclassified family histories all contributing. The researchers caution that larger haplotype studies and archival research are needed to confirm the founder hypothesis, but the work opens a compelling new frontier in understanding how a single gene can shape both motor degeneration and dementia vulnerability.

Subject of Research: SPG4/SPAST mutations and their association with hereditary spastic paraplegia and plaque-only dementia

Article Title: SPG4 and Dementia: Expanding the Clinical Spectrum

Article References: SPG4 and Dementia: Expanding the Clinical Spectrum. (n.d.). https://doi.org/10.1002/acn3.70371

Image Credits: AI Generated

DOI: 10.1002/acn3.70371

Keywords: hereditary spastic paraplegia, SPG4, SPAST, spastin, dementia, amyloid plaques, plaque-only dementia, APOE ε4, genetics, neurodegeneration, amyloid PET, founder effect

The experimental logic behind the study is rooted in what scientists call the microbiota-gut-brain axis, the bidirectional communication network linking the intestinal microbial community, the gut epithelial barrier, the immune system, and the central nervous system. In recent years, disruptions in this axis have been implicated in a range of neurological conditions, from depression and autism to Parkinson’s and Alzheimer’s disease. In Alzheimer’s specifically, an imbalanced gut microbiota can compromise the intestinal mucosal barrier, allowing bacterial products such as lipopolysaccharides and amyloid-like molecules to circulate, activate microglia, and drive chronic neuroinflammation, which in turn accelerates neurodegeneration.

To model the disease, the researchers injected Wistar albino rats intraperitoneally with aluminium chloride at 50 milligrams per kilogram of body weight and D-galactose at 100 milligrams per kilogram for seven consecutive days. Aluminium is a known neurotoxin that disrupts metal homeostasis and promotes iron-mediated lipid peroxidation, while D-galactose generates reactive oxygen species that damage proteins, lipids, and DNA. Together, the two chemicals reliably produce the pathological signature of Alzheimer’s in rodents: beta-amyloid plaque accumulation, neurofibrillary tangles, declining neurotransmitter levels, and widespread oxidative injury. The team then tested three different probiotic regimens, co-administration alongside the toxins, a prophylactic protocol in which the probiotic preceded the toxins, and a therapeutic protocol in which the probiotic followed the toxin exposure, and compared all of them against a memantine-treated positive control group.

The histopathological results were striking. Congo red staining of brain sections revealed that rats exposed to aluminium chloride and D-galactose developed dense amyloid plaque deposits, cerebral amyloid angiopathy, and neurofibrillary tangles in the hippocampus and cerebral cortex. In the rats that received L. fermentum NCDC701, whether before, during, or after toxin exposure, these abnormalities were markedly reduced, with hippocampal tissue appearing largely normal, cells intact, and no signs of necrosis. Notably, the probiotic-treated groups appeared to outperform memantine, the standard anti-Alzheimer drug used as a positive control, which left some residual plaques and angiopathy. In the colon, haematoxylin and eosin staining showed that the probiotic restored epithelial integrity and reduced the infiltration of inflammatory leukocytes and neutrophils that the toxin regimen had caused.

Biochemical assays using ELISA quantified the molecular shifts underlying these tissue-level changes. The toxin-exposed rats showed elevated concentrations of beta-amyloid peptides 1-40 and 1-42 in both brain and serum, along with depressed levels of the inhibitory neurotransmitter GABA and the monoamine serotonin. Supplementation with L. fermentum NCDC701 reversed both trends, lowering amyloid peptide concentrations and restoring GABA and serotonin toward control levels. This is consistent with the strain’s in vitro profile: the researchers measured GABA production by NCDC701 at approximately 99.43 millimolar, suggesting the bacterium is a substantial neurotransmitter factory. Because GABA decline is considered a contributor to Alzheimer’s symptomatology, and because reduced serotonin has been linked to the aggressive behaviors seen in dementia patients, the neuromodulatory capacity of this strain is of particular interest.

The probiotic also rebalanced the immune chemistry of both brain and colon. Pro-inflammatory cytokines IL-6 and TNF-alpha, which surged after toxin exposure, fell significantly in all three probiotic groups, while the anti-inflammatory cytokine IL-10 rose. At the transcriptional level, RT-qPCR showed that NCDC701 suppressed the expression of p65, a key component of the NF-kappaB inflammatory signaling complex, along with COX-2 and iNOS, two enzymes that amplify inflammatory and oxidative damage, in both brain and colonic tissue. Simultaneously, the strain boosted the activity of the antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase, which the toxin regimen had suppressed, thereby restoring the tissue’s capacity to neutralize free radicals.

One of the most clinically relevant findings concerned the gut barrier itself. The mRNA expression of tight junction proteins, zonula occludens-1, occludin, and claudin-1, dropped sharply in the colons of toxin-exposed rats, reflecting a leaky intestinal epithelium that permits bacterial endotoxins to enter circulation. L. fermentum NCDC701 restored the expression of all three proteins, effectively re-sealing the barrier. This matters because a compromised gut lining is thought to be a gateway event in the gut-brain axis model of neurodegeneration: it allows lipopolysaccharides and other microbial products to trigger systemic inflammation, activate microglia in the brain, and promote amyloid aggregation. By reinforcing the barrier, the probiotic may be cutting the disease process off at one of its upstream sources.

Deep sequencing of the V3-V4 region of the 16S rRNA gene in faecal samples revealed how profoundly the toxin regimen disturbed the gut ecosystem, and how effectively the probiotic repaired it. Aluminium chloride and D-galactose lowered the Shannon diversity index and the number of observed operational taxonomic units, signatures of dysbiosis. The Firmicutes to Bacteroidetes ratio, 1.435 in healthy controls, fell to 1.03 in the disease model but rebounded to approximately 1.4 in all probiotic-treated groups. Beneficial genera such as Lactobacillus, Prevotella, Ruminococcus, and Oscillospira, the latter known to support IL-10-producing regulatory T cells, all recovered after probiotic administration, while pathogenic taxa including Spirochaetes, Porphyromonadaceae, Coprococcus, Clostridium, and Allobaculum receded. The disease model also showed elevated Proteobacteria, a phylum increasingly recognized as a microbial marker of dysbiosis and inflammation, which declined with treatment.

Metabolite analysis tied these microbial shifts to functional chemistry. Gas-liquid chromatography of faecal samples showed that the disease model was enriched in propionate, echoing previous reports of elevated propionic acid in the blood of Alzheimer’s patients, while butyrate and total short-chain fatty acids were depressed. Probiotic treatment restored the short-chain fatty acid profile, increasing butyrate, a molecule that fuels colonocytes, strengthens epithelial tight junctions, and can modulate anti-inflammatory pathways through G-protein-coupled receptors. Because short-chain fatty acids can enter the circulation, cross the blood-brain barrier, and influence vagal, endocrine, and immune signaling, their restoration provides a plausible mechanistic bridge between the microbial changes observed in the colon and the biochemical recovery documented in the brain.

The authors are candid about the study’s limitations. The biochemical and molecular analyses used small groups of three animals per condition, a constraint imposed by resource limitations during the COVID-19 pandemic, and no human clinical trials have yet tested the strain. Larger and more diverse cohorts will be needed to confirm the statistical robustness and generalizability of the results, and translational studies will be essential before any commercial application. Nevertheless, the convergence of histological, biochemical, transcriptional, microbiological, and metabolomic evidence around a single probiotic strain is unusual and compelling. If future work validates these findings in humans, L. fermentum NCDC701 could represent a new class of adjunct therapy for Alzheimer’s disease, one that works not by attacking plaques directly in the brain, but by rebuilding the microbial and barrier defenses of the gut, and letting the microbiota-gut-brain axis carry the benefit upward.

Subject of Research: Probiotic modulation of the gut-microbiota-brain axis in an aluminium chloride and D-galactose-induced rat model of Alzheimer's disease

Article Title: Ameliorative action of probiotics on the neurotoxicological effect of Aluminium chloride and D-galactose

Article References: Dasriya, V. L., Kumari, M., Ranveer, S., Behare, P., Vij, S., & Puniya, A. K. (2025). Ameliorative action of probiotics on the neurotoxicological effect of Aluminium chloride and D-galactose. Discover Toxicology, 2(1), Article 6. https://doi.org/10.1007/s44339-025-00022-0

Image Credits: AI Generated

DOI: 10.1007/s44339-025-00022-0

Keywords: probiotics, Limosilactobacillus fermentum, Alzheimer's disease, gut-brain axis, amyloid plaques, neuroinflammation, oxidative stress, GABA, short-chain fatty acids, gut microbiota, tight junction proteins, aluminium chloride

The core problem the authors identify is phenotypic heterogeneity. Sporadic Alzheimer’s disease accounts for roughly 90 percent of cases and is diagnosed clinically using cognitive testing, supported by amyloid and tau biomarkers in cerebrospinal fluid, blood plasma and PET imaging. But on the neuropathological level, the disease is far more complex than a simple case-versus-control division suggests. Amyloid plaques of extracellular beta-amyloid and intracellular neurofibrillary tangles of hyperphosphorylated tau are the hallmark lesions, yet comorbid pathology is the norm rather than the exception in the aging brain. Cerebral amyloid angiopathy, alpha-synuclein Lewy bodies, TDP-43 inclusions and granulovacuolar degeneration bodies frequently co-occur with hallmark Alzheimer lesions, sometimes at striking frequencies: TDP-43 inclusions can be found in up to 57 percent of Alzheimer’s patients and Lewy bodies in over 60 percent.

This complexity has direct consequences for genetic research. Twin studies estimate the heritability of sporadic Alzheimer’s disease at around 60 to 80 percent, and SNP-based heritability estimates rise from roughly 0.25 to 0.34 in clinical cohorts to 0.36 to 0.59 when autopsy or biomarker confirmation is used. More than 75 risk loci have now been associated with Alzheimer’s disease through GWAS, implicating pathways ranging from APP and tau processing to endocytosis, lipid metabolism and innate immunity. Yet clinical misclassification introduces type I and type II errors into large-scale studies, and some discovered signals may reflect co-pathologies or misdiagnosed subgroups rather than pure Alzheimer’s pathogenesis. The authors argue that smaller, deeply phenotyped cohorts can outperform ever-larger clinical samples because phenotypic accuracy is what limits statistical power, not sample size alone.

The review traces how this shift has already paid off for the hallmark lesions. Studies on the Religious Orders Study and Rush Memory and Aging Project (ROSMAP) cohorts, which follow cognitively normal individuals with longitudinal evaluation and brain donation, linked a CR1 intronic variant to increased neuritic plaque burden. Later work testing 83 risk variants from the largest clinical Alzheimer’s GWAS in a cohort of over 4,000 individuals found that BIN1, CR1 and COX7 variants increased neurofibrillary tangle burden while MME decreased it, and that BIN1, APH1B and FERMT2 variants raised neuritic plaque risk while MME, EED/PICALM and RBCK1 were protective. A genome-wide significant association between APOE and tangle pathology was repeatedly replicated, and an intronic PTPRD signal emerged in larger ROSMAP GWAS and was independently replicated.

Larger multicenter efforts extended these findings. The Alzheimer’s Disease Genetics Consortium performed GWAS of neuropathological phenotypes in nearly 5,000 individuals, confirming genome-wide significant APOE associations with all investigated lesions and identifying protective signals for GALNT7, ABCG1 and IER5I with neuritic plaques. A study of more than 7,000 autopsied participants from ROSMAP, NACC and ACT cohorts found APOE significantly associated with amyloid score, Braak stage and CERAD neuritic plaque score, plus a genome-wide significant BIN1 effect on higher Braak stages, with ABCA7, PTK2B, CR1, SNX1, FERMT2 and CELF/SPI1 raising plaque burden and PICALM, INPP5D, ZCWPW1 and SORL1 lowering it. Sex-stratified analyses added nuance, revealing a male-specific protective signal near TSPAN13 for tangle presence, though the authors caution that reduced statistical power in stratified analyses means such findings require independent replication.

Perhaps the most striking example of the approach’s value comes from primary age-related tauopathy, or PART, a condition in which tau lesions indistinguishable from Alzheimer’s occur without amyloid plaques and with limited cognitive consequences. A GWAS confined to neuropathologically confirmed PART cases uncovered a genome-wide significant locus on chromosome 4, with functional validation pointing to JADE1 as the plausible risk gene for tau pathology. Notably, the effect alleles in this locus were independent of earlier suggestive signals, illustrating how restricting cohorts to precisely defined pathological entities can reveal biology that overlapping, heterogeneously composed cohorts dilute or obscure.

Co-pathologies show equally illuminating genetic patterns. For cerebral amyloid angiopathy, found in up to 90 percent of Alzheimer’s cases, the APOE epsilon4 allele is specifically linked to capillary-involving Type I disease, while epsilon2 is more frequent in Type II. Beyond APOE, CR1 and UNC5C were implicated in hypothesis-driven studies, and a GWAS in over 800 individuals identified the long noncoding RNA locus LINC-PINT, associated with decreased CAA burden in APOE epsilon4-negative individuals and supported by in vitro evidence of neuroprotection. A protective APOC2 polymorphism in a large postmortem GWAS was later shown by colocalization to reflect reduced APOE expression in brain microglia, demonstrating how post-GWAS fine-mapping can redirect interpretation from the nearest gene to the true molecular driver.

For TDP-43 pathology and the related entity LATE (limbic-predominant age-related TDP-43 encephalopathy), much of the genetic insight has come from frontotemporal lobar degeneration research, where neuropathology-centered GWAS revealed TMEM106B, DPP6, UNC13A, HLA-DQA2 and TNIP1 as risk factors, with distinct loci emerging for specific FTLD-TDP subtypes. In the Alzheimer’s context, APOE epsilon4 allele count correlates with TDP-43 burden, and TMEM106B was confirmed as associated with LATE neuropathological change, alongside suggestive signals for GRN, SORL1 and TPCN1. Both TMEM106B, a lysosomal transmembrane protein whose C-terminal domain can form amyloid fibrils, and GRN, encoding the lysosomal growth factor progranulin, implicate lysosomal dysfunction as a shared mechanism spanning Alzheimer’s and TDP-43 proteinopathies. For Lewy body pathology, APOE and BIN1 are firmly established Alzheimer’s risk genes whose links to alpha-synuclein aggregates remain contested; one stratified GWAS concluded they raise Alzheimer’s risk regardless of Lewy body status, while BLMH and ZNF365 signals emerged for Lewy body presence in Alzheimer’s-negative individuals. Granulovacuolar degeneration, an underexplored lesion strongly tied to tau pathology, endocytosis, autophagy and necroptosis, showed APOE and APH1B associations that network modeling suggested are largely indirect, mediated through amyloid and tangle pathology.

The authors are candid about the caveats. Neuropathological cohorts are necessarily small because donated brain tissue is limited, forcing reliance on multi-center compilations that introduce inter-observer variability, differing staining protocols and harmonization challenges, though initiatives like BrainNet Europe have shown that immunohistochemistry with standardized antibodies and dichotomous diagnostic approaches yield the most robust results. Overlapping study populations across published GWAS also limit independence of findings, underscoring the need for new, standardized cohorts. Moreover, GWAS lead variants are often not the causal variants, and the nearest protein-coding gene is not necessarily the affected gene, since most hits sit in noncoding regulatory regions; gene prioritization and functional validation remain essential before mechanistic claims can be made.

Even so, the message of the review is unambiguous: bigger is not always better. Combining genetic data with detailed neuropathology enables refinement of clinical GWAS signals, discovery of variants tied to the burden of specific lesions rather than a diagnostic label, network analyses that position APOE’s effects on tau as largely indirect through amyloid and vascular pathology, and identification of overlapping genetic risk across disease boundaries. As the first disease-modifying Alzheimer’s therapies arrive, understanding which genes drive which lesions, and how co-pathologies shape disease trajectory, could enable the patient stratification that clinical trials increasingly demand, and point toward treatments addressing the full neuropathological spectrum rather than a single pathological feature.

Subject of Research: Neuropathology-centered genome-wide association studies of Alzheimer's disease and overlapping co-pathologies

Article Title: A new era of genome-wide association studies in the field of Alzheimer’s disease and overlapping co-pathologies: lessons learned from a neuropathology-centered approach

Article References: A new era of genome-wide association studies in the field of Alzheimer’s disease and overlapping co-pathologies: lessons learned from a neuropathology-centered approach. (n.d.). https://doi.org/10.1007/s00401-026-03085-4

Image Credits: AI Generated

DOI: 10.1007/s00401-026-03085-4

Keywords: Alzheimer's disease, genome-wide association studies, neuropathology, amyloid plaques, neurofibrillary tangles, cerebral amyloid angiopathy, TDP-43, Lewy bodies, APOE, TMEM106B, co-pathologies, LATE

Alzheimer’s disease is the most common cause of dementia, characterized by a slow, relentless loss of memory and cognition that accompanies the accumulation of amyloid-beta peptide in the brain, the death of neurons, and the formation of tangled proteins inside cells. Although decades of research have focused on amyloid itself, the upstream molecular switches that determine whether neurons resist or succumb to these insults remain only partly understood. The new work zeroes in on one such switch: a regulatory axis connecting a long non-coding RNA, a microRNA called miR-150, and the WNT/beta-catenin pathway, a signaling system long implicated in cell survival and brain maintenance.

Long non-coding RNAs, or lncRNAs, are transcripts longer than 200 nucleotides that are not translated into proteins. Once dismissed as transcriptional noise, they are now recognized as master regulators of gene expression, capable of sponging up microRNAs, guiding protein complexes to DNA, and modulating signaling pathways. In cancer research, lncRNAs that interact with the WNT/beta-catenin pathway have been extensively characterized, but their roles in neurodegeneration are far less explored. The team behind the new study set out to determine whether one particular lncRNA, Loc646329, might influence the course of Alzheimer’s disease.

The researchers began where many modern investigations do: with publicly available human sequencing data. By analyzing datasets of brain samples from Alzheimer’s patients and healthy controls, they examined how Loc646329 and miR-150 behave in the diseased brain. The datasets, including the publicly archived GSE63501 and GSE67333 series, provided the initial evidence that these two RNA molecules are implicated in the disease state, motivating the laboratory experiments that followed.

To test the mechanism directly, the team turned to SH-SY5Y cells, a human neuroblastoma cell line widely used to model neuronal biology. Fluorescence in situ hybridization revealed that Loc646329 resides predominantly in the cytoplasm, the cellular compartment where a lncRNA would need to be if it were to interact with microRNAs. Two complementary techniques then established the physical link: AGO2-RNA immunoprecipitation, which captures RNA molecules bound to the Argonaute 2 protein at the heart of the microRNA silencing machinery, and dual-luciferase reporter assays, which confirmed that miR-150 directly targets Loc646329. Together, these experiments painted a picture of Loc646329 as a competing endogenous RNA, or molecular sponge, that sequesters miR-150 and prevents it from dampening downstream targets.

The functional consequences of this interaction were tested under brutal conditions: the cells were exposed to aggregated amyloid-beta 1-42, the toxic peptide that accumulates in Alzheimer’s brains. When Loc646329 was overexpressed, the cells fared measurably better. A battery of assays told a consistent story. CCK-8 assays showed improved metabolic viability. EdU incorporation revealed that more cells retained proliferative capacity. Annexin V-FITC/PI flow cytometry and TUNEL staining, two independent measures of programmed cell death, both showed reduced apoptosis. In other words, raising the levels of this single non-coding RNA helped neurons withstand an otherwise lethal amyloid assault.

The mechanistic core of the study lies in what happens downstream of miR-150. The WNT/beta-catenin pathway is a major regulator of neuronal survival, and its dysfunction has been repeatedly linked to Alzheimer’s disease. A key player in this pathway is GSK3beta, an enzyme whose phosphorylation status determines whether beta-catenin, the pathway’s central messenger, is stabilized and allowed to travel to the nucleus to switch on survival genes, or is tagged for destruction. The researchers found that Loc646329 overexpression increased GSK3beta phosphorylation and stabilized beta-catenin, effectively turning up the volume on WNT signaling. Critically, when the team introduced synthetic miR-150 mimics into the cells, the protective effects of Loc646329 on these signaling events were blunted, indicating that the lncRNA’s benefits depend at least partly on its ability to neutralize miR-150.

Cell culture findings, however compelling, are only a prelude to the real test: does this matter in a living brain? To find out, the researchers used APP/PS1 mice, a transgenic strain that carries human amyloid precursor protein and presenilin mutations and progressively develops amyloid plaques and memory deficits resembling Alzheimer’s disease. Using stereotaxic injection, a surgical technique that allows precise delivery of material into defined brain regions, the team introduced an adeno-associated virus carrying the Loc646329 gene directly into the animals’ hippocampus, the brain structure essential for forming new memories.

The results were striking. In the Morris water maze, a standard behavioral test in which mice must learn the location of a hidden platform using spatial cues, the treated animals found the platform more efficiently than their untreated counterparts, demonstrating improved spatial learning and memory. Biochemical and histological analysis revealed the molecular underpinnings of this improvement: the treated mice had a reduced burden of amyloid-beta plaques and increased activation of beta-catenin in the injected brain region. The study thus connected the molecular sponge hypothesis to meaningful outcomes in an intact, diseased brain, a translation that many non-coding RNA studies never achieve.

The authors are careful to frame these findings as preclinical evidence rather than a therapeutic breakthrough. The work was conducted in cell lines and in a single mouse model, and the researchers themselves note that validation in primary neurons, human-derived neuronal models, and clinical samples is required before Loc646329’s therapeutic relevance can be established. delivering RNA-based therapies to the human brain remains a formidable challenge, and microRNA networks are notoriously context-dependent, with the same microRNA sometimes producing different effects in different cell types. Nevertheless, the study adds a compelling new name to the growing roster of non-coding RNAs implicated in Alzheimer’s disease, and it strengthens the case that the WNT/beta-catenin pathway is a druggable node worth pursuing. If subsequent studies confirm that boosting Loc646329 or blocking miR-150 can safely protect human neurons, the humble sponge molecule could one day inform entirely new strategies against a disease that currently has no cure.

Subject of Research: The role of the long non-coding RNA Loc646329 in regulating Alzheimer's disease-related pathology through the miR-150/WNT/beta-catenin signaling axis.

Article Title: LncRNA Loc646329 modulates Alzheimer’s disease-related phenotypes through the miR-150/WNT/β-catenin axis in cellular and APP/PS1 mouse models

Article References: Abdi, K., Amiri, M., Asadalizadeh, M., Khanmirzaei, A., Javanmard, A.-R., Rezaeimirghaed, O., Hajiesmaeili, M., & Ghaderian, S. M. H. (2026). LncRNA Loc646329 modulates Alzheimer’s disease-related phenotypes through the miR-150/WNT/β-catenin axis in cellular and APP/PS1 mouse models. Molecular Biology Reports, 53(1), Article 1594. https://doi.org/10.1007/s11033-026-12734-6

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12734-6

Keywords: Alzheimer's disease, lncRNA Loc646329, miR-150, WNT/beta-catenin signaling, neurodegeneration, amyloid-beta, neuronal apoptosis, APP/PS1 mice, non-coding RNA, hippocampus, gene regulation, GSK3beta phosphorylation